Navigation Links
Sorrento Announces the Unexpected Death of its Chief Business Officer
Date:7/31/2014

SAN DIEGO, July 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30.

"Sorrento is deeply saddened and shocked by the loss of our dear friend and colleague. Our immediate thoughts go to Amar's family and friends," said Henry Ji, Ph.D., Sorrento's President and Chief Executive Officer.

Mr. Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where he served as SVP and Chief Business Officer since December 2010. Previously, Mr. Singh served as: Chief Operating Officer of Spectrum Pharmaceuticals, where he led the commercial and business development teams; VP and Chief Commercial Officer at Novacea responsible for securing partnerships; and Chief Commercial Officer at Abraxis where he led the launch of Abraxane®. Prior to Abraxis, Mr. Singh held multiple commercial leadership positions in the oncology franchise at Hoffman-La Roche for over 10 years. Mr. Singh holds an M.B.A. from the Stern School of Business at New York University and a B.A. from the University of North Carolina at Chapel Hill.

About Sorrento Therapeutics, Inc.
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bispecific therapeutic antibodies, and ADCs.

More information is available at www.sorrentotherapeutics.com.


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor
2. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
3. Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
4. Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
5. Sorrento Therapeutics Adopts Stockholder Rights Plan
6. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
7. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
8. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
9. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
10. Sorrento Therapeutics Completes IgDraSol Merger
11. Sorrento Therapeutics to Present at Two Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... AMSTERDAM , Feb. 17, ... connected health offerings at the  ...  (NYSE: PHG,AEX: PHIA), a global ... a broad range of population ... personal health solutions, fully integrated in a ...
(Date:2/17/2017)... Feb. 17, 2017  Noble Capital Markets announced today ... Inc. (Nasdaq: EPIX ). The report was ... Raja , PhD. ESSA Pharmaceuticals is a ... prostate cancer (CRPC). Its lead compound EPI-506, is a ... domain of the androgen receptor, thereby has potential to ...
(Date:2/16/2017)... MADISON, N.J. , Feb. 16, 2017 ... leading provider of diagnostic information services, today announced that ... Admired Companies" for 2017 by Fortune. ... only six companies in the "Health Care: Pharmacy and ... the only diagnostic information services company to attain the ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a ... Rogers, was named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. ... have made notable contributions to the staffing industry over the last twelve months. ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses ... Foundation Summit from February 21 - 23 in Beaver Creek, CO. It was announced ... the Summit’s second year in Beaver Creek, hosting over 60 faculty members and addressing ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... took over 10 years of research, development and clinical trials, the founder of ... is a patented compound of FDA approved ingredients that when infused into alcohol, ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... financial planning services to families and entrepreneurs in the Birmingham area, is announcing ... mother who needs assistance with her medically challenged son, Anius. , Anius is ...
(Date:2/16/2017)... ... February 16, 2017 , ... PRESS RELEASE, FOR IMMEDIATE RELEASE:, ... David A Doege is excited to announce the launch of Doege Development, LLC, ... builds, design build, and site improvements. , Mr. Doege says, "I am so ...
Breaking Medicine News(10 mins):